Briacell Therapeutics Corp Stock Price, News & Analysis

BriaCell Therapeutics has entered into a multi-year, non-exclusive license agreement with ImaginAb to utilize its advanced CD8 ImmunoPET imaging technology for analyzing tumor-attacking CD8 T cells in breast cancer patients. This partnership supplements BriaCell's ongoing Phase I/IIa study and aims to enhance the assessment of safety and efficacy for its immunotherapy treatments. The collaboration is expected to accelerate drug development and improve patient care, with continued clinical doses and technical support from ImaginAb.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has announced the opening of recruitment for a Phase I/IIa clinical study in collaboration with Incyte to evaluate the combination of Bria-IMT™, retifanlimab, and epacadostat for advanced breast cancer treatment. This study follows previous treatments of two patients and aims to explore novel therapeutic combinations. BriaCell expresses optimism regarding the potential effectiveness and safety of this combination, underscoring its commitment to innovative cancer therapies.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW), a clinical-stage biotechnology company focused on immunotherapies for advanced breast cancer, announced two upcoming virtual presentations by CEO Dr. William V. Williams. He will present at the Access to Giving Conference on July 14, 2021, and the Q3 Investor Summit on August 17, 2021. Additionally, he will speak at the SNN Network Summer Virtual Event on August 18, 2021. Each event will offer opportunities for investor meetings and live webcasts.

BriaCell Therapeutics Corp. (BCTX, BCTXW) is expanding its breast cancer immunotherapy platform to include treatments for prostate, melanoma, and non-small cell lung cancers. The company has announced the development of three new therapies: Bria-Pros™, Bria-Mel™, and Bria-Lung™, leveraging an off-the-shelf personalized immunotherapy approach. Bria-OTS™ for advanced breast cancer is expected to enter clinical trials in 2021, while the new therapies are anticipated to commence trials in 2022. BriaCell aims to address the significant unmet medical needs in these cancer types.

BriaCell Therapeutics Corp. announced it raised US$12.88 million through the exercise of 2,425,300 warrants at US$5.3125 each. The funds will support the advancement of its clinical and research pipeline, focused on targeted immunotherapies for advanced breast cancer. Recently, BriaCell reported 12 months of overall survival benefit for patients in its Phase I/IIa study. The company aims to explore additional applications of its technology across other cancer types.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announces a corporate and clinical update call scheduled for June 16, 2021, at 4:30 p.m. ET. CEO Dr. William V. Williams will lead the discussion, covering company updates and advancements in their targeted immunotherapies for advanced breast cancer. Interested participants must pre-register for the call through a provided link, and those unable to do so can join by phone. A replay of the call will be available until June 30, 2021. Pre-submitted questions will be addressed during the call.

BriaCell Therapeutics Corp. (NASDAQ: BCTX, BCTXW) has successfully completed a private placement, raising US$27.2 million from the sale of 4,370,343 common shares and 800,000 pre-funded warrants. Each share was sold at US$5.26 and warrants at US$5.25. The net proceeds will be utilized to further enhance its research and development pipeline. ThinkEquity served as the placement agent, earning an 8.0% commission on gross proceeds. Additionally, compensation warrants will be issued to the agent at an exercise price of US$6.19.

BriaCell Therapeutics Corp. announced a private placement with accredited investors, expecting to raise approximately US$27.2 million from the sale of 5,170,343 units at US$5.26 each. Each unit consists of one share of common stock and one warrant with an exercise price of US$6.19, maturing in five and a half years. The closing date for this transaction is set for June 7, 2021, pending customary conditions. The securities will not be registered under the Securities Act, and BriaCell will file a registration statement for resale compliance.

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) reports significant overall survival data for advanced breast cancer patients treated with its candidate, Bria-IMT™. Patients demonstrated a 12.0 months average overall survival, with 13.4 months for those with 2+ HLA matches and 12.5 months for Grade I/II tumors. A top responder achieved 21.4 months survival and complete resolution of an orbital tumor. These results significantly outperform historical treatments, which average 7.2-9.8 months survival. The findings position BriaCell as a promising option for patients resistant to existing therapies.